The role of fludarabine in hematological malignancies.
Blood Rev
; 8(3): 125-34, 1994 Sep.
Article
em En
| MEDLINE
| ID: mdl-7819814
ABSTRACT
Fludarabine monophosphate, a synthetic nucleoside analog, has been shown to have considerable activity in a number of lymphoid malignancies. In chronic lymphocytic leukemia the response rates can exceed 70% with a considerable proportion of complete remissions being attained. These rates are markedly superior to earlier therapies with which complete remission was uncommon. It also has significant activity in previously treated patients for whom effective salvage regimens were unsatisfactory. In addition, fludarabine shows substantial activity in low grade non-Hodgkin's lymphoma, both as initial treatment and as salvage therapy. Fludarabine is effective in Waldenstrom's macroglobulinemia and is active in other low grade lymphoid malignancies. Major toxicities are reversible myelosuppression and depletion of T lymphocytes. The use of fludarabine in hematological malignancies will be reviewed, with reference to its mode of action and future use in combination therapies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vidarabina
/
Linfoma não Hodgkin
/
Leucemia Linfocítica Crônica de Células B
/
Macroglobulinemia de Waldenstrom
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Blood Rev
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
1994
Tipo de documento:
Article